Market Overview

Global Influenza Vaccines Market Outlook 2018-2028

Share:

Global Influenza Vaccines Market Outlook 2018-2028

PR Newswire

NEW YORK, August 6, 2018 /PRNewswire/ -- Forecasts for Trivalent Influenza Vaccines (TIV) & Quadrivalent Influenza Vaccines (QIV), Revenue Forecasts and Analysis of Pipeline Developments for Fluzone / VaxiGrip, Seqirus, Fluarix / FluLaval, FluMist / Fluenz, FluBlok and Other

Read the full report: https://www.reportlinker.com/p04763515

The latest report from business intelligence provider visiongain offers comprehensive analysis of the global influenza vaccines market. Visiongain assesses that this market will generate revenues of $3.5 billion in 2018.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector. Visiongain's new study tells you and tells you NOW.
In this brand new 138-page report you find 63 in-depth tables, charts and graphs -all unavailable elsewhere.
The report provides clear detailed insight into the global Influenza market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope
Visiongain's new investigation shows revenue predictions at overall world market, submarket, company, product and national level.

That study gives individual analysis for two influenza vaccine submarkets, which are further divided by vaccine technologies:
- Trivalent Influenza Vaccines (TIV)
- Quadrivalent Influenza Vaccines (QIV)

Our new analysis also shows you revenue predictions for the vaccines produced by these five market leaders: and their market share:
- Sanofi Pasteur
- GSK
- Seqirus
- AstraZeneca
- Protein Science Corporation.
- Others

From 2018, large pharmaceutical companies and other biopharma specialists can prosper in that market. See how, discovering organisations' potentials.

Our report analyses the vaccines in research and development and assess their prospects once they enter the market. The R&D pipeline discusses:
- Seasonal Influenza vaccines in development
- Universal Influenza vaccines in development

The report includes forecasts to 2028 and analysis of pipeline developments for the following specific vaccines:
- Fluzone / VaxiGrip
- Seqirus
- Fluarix / FluLaval
- FluMist / Fluenz
- FluBlok
- Other

The study shows you prospects for those drug sales in developed and developing regions. There see individual revenue forecasts to 2028 for 11 countries:
- United States
- Japan
- The EU 5 -Germany, France, United Kingdom, Italy and Spain.
- Brazil, Russia, India and China

Who should read this report?
- Anyone within the influenza vaccines value chain.
- Pharmaceutical companies
- Vaccine manufacturers
- Healthcare biotech companies
- Generics and biosimilar producers
- Drug delivery companies and other technology providers
- Contract/clinical research organisations (CROs)
- Pharma contract manufacturers,
- Pharma/healthcare wholesale and distribution companies
- Medical device companies
- Healthcare diagnostics companies
- R&D specialists
- Business development managers
- Marketing managers
- Technologists
- Suppliers
- Investors
- Banks
- Government agencies
- Contractors

Read the full report: https://www.reportlinker.com/p04763515

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

Cision View original content:http://www.prnewswire.com/news-releases/global-influenza-vaccines-market-outlook-2018-2028-300692303.html

SOURCE Reportlinker

View Comments and Join the Discussion!